Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1811-1813

  Di Fiore, F ^a   Rigal, O ^a   Menager C ^a   Michel, P ^a   Pfister, C ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical toxicities; Renal carcinoma; Survival; TKI

Indexed keywords

SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADVANCED CANCER; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; COMORBIDITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; SKIN TOXICITY; AGED; KIDNEY TUMOR; MIDDLE AGED; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SURVIVAL RATE;

EID: 84855999342     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.507     Document Type: Article

References (13)

1. Bellmunt J, Eisen T, Fishman M, Quinn D (2011) Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 78: 24-32
2. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383 (Pubitemid 17055592)
3. Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K (2010) How to select targeted therapy in renal cell cancer. Ann Oncol 21(Suppl 7): vii59-vii62
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134 (Pubitemid 46089673)
5. George S, Lechner T, Li S, Cohen DP, Demetri GD (2011) Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU). Gastrointestinal Cancers Symposium. J Clin Oncol 29(Suppl 4): abstract 38
6. Motzer RJ Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124 (Pubitemid 46089672)
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540 (Pubitemid 29368255)
8. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T (2011) Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 104: 741-745
9. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773
10. Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 18: 1117-1125
11. Schmidinger M, Bellmunt J (2010) Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 36: 416-424
12. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417
13. van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99: 259-265